ATC Group: N05AH04 Quetiapine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05AH04 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05A Antipsychotics
4 N05AH Diazepines, oxazepines and thiazepines
5 N05AH04 Quetiapine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.4 g

Active ingredients in N05AH04

Active Ingredient Description
Quetiapine

Quetiapine is an atypical antipsychotic agent. Quetiapine and the active human plasma metabolite, norquetiapine interact with a broad range of neurotransmitter receptors.

Related product monographs

Title Information Source Document Type  
ATROLAK Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SEROQUEL Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TOMEL Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
TRUVALIN Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Cyprus (CY)

Finland (FI)

France (FR)

Germany (DE)

Israel (IL)

Japan (JP)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Singapore (SG)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.